D-Dimer测试市场份额，规模，趋势，行业分析报告，由产品（分析仪，试剂和耗材）;通过测试方法[酶联免疫吸附测定（ELISA），乳胶增强免疫浊度测定，荧光免疫测定，其他];通过申请;通过最终使用;按地区;分部预测，2020 - 2027年

发布日期：1月2021
页数：108
格式：PDF.
报告ID：PM1788
基数：2019年
历史数据：2016 - 2018年

报告摘要

The global D-dimer testing market was valued at USD 1.24 billion in 2019 and is expected to grow at a CAGR of 4.4% during the forecast period. Increasing prevalence of blood clotting genetic disorders, a spike in Venous Thromboembolism (VTE), and the rising need for the next generation PoC D-dimer tests are the key factors responsible for the market growth.

The shift of testing services from traditional to the PoC D-dimer testing enables faster test results, rapid diagnosis, reduction in patient’s waiting time, and the improved patient journey. Such resounding benefits of PoC testing would boost its uptake among consumers. Moreover, the rising cardiovascular and pulmonary diseases, in severe cases, result in life-threatening blood clot issues, thereby inducing market growth.

The normal range for the D-dimer is measured at less than 0.5 and positive is greater than 0.5. Under the abnormal medical case, D-dimer levels get decreased, which is measured by specific antibodies. The test is pretty useful in the diagnosis of intravascular fibrinolysis and coagulation.

Elevated levels of D-dimer are found in the cases of deep vein thrombosis, pulmonary embolism, bleeding, trauma, liver disease, malignancy, and chronic cases of a hypercoagulable state. In the blood, plasmin is specifically neutralized by the alpha 2 anti-plasmin, blocking fibrinogen lysis and localizes fibrinolysis on fibrin clots. This clot is further degraded by plasmin into several by-products such as D-dimers.

了解有关此报告的更多信息：request for sample pages

Industry Dynamics

Growth Drivers
Increase in the prevalence of VTE and blood-clot disorders creating a demand for the need for D-dimer testing. According to the estimates of the Centers for Disease Control and Prevention (CDC), each year in the U.S. alone, on average 75,000 die due to the VTE. The innovations in aptamers as a replacement of antibodies are considered as a cost-effective and highly efficient approach.

适体是短的寡核苷酸，折叠成明确定义的架构，以与特定蛋白质结合。在结合过程中，它们抑制蛋白质和蛋白质相互作用并引出治疗效果。适体是稳定的，与抗体相比，具有较长的保质期和价格实惠，可以大规模生产用于均匀的测定和其他诊断测试。几个市场研究活动表明，D-二聚体的升高可以作为许多临床适应症中的有价值的生物标志物，包括冠状动脉紊乱，心房颤动和艾滋病毒感染。

D-Dimer测试市场报告范围

The market is primarily segmented on the basis of product, testing method, application, end-use, and region.

由产品	By Testing Method	通过申请	通过最终使用	按地区
Analyzers 试剂和耗材	酶联免疫吸附试验（ELISA）乳胶增强免疫浊度测定 Fluorescence Immunoassays Others	深静脉血栓形成（DVT）肺栓塞（PE） Disseminated Intravascular Coagulation (DIC) Others	医院学术研究机构诊断中心 Others	北美（美国，加拿大）欧洲（法国，德国，英国，意大利，西班牙，荷兰，奥地利） Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea) 拉丁美洲（巴西，墨西哥，阿根廷）中东和非洲（沙特阿拉伯，阿联酋，以色列，南非）

了解有关此报告的更多信息：request for sample pages

Insight by Product

基于该产品，全球D-Dimer测试行业分为分析仪和试剂和耗材。2019年，耗材市场分部占收入份额最大。这种高份额归因于D-Dimer测试行业的即用常用的试剂和耗材的频繁可用性。消耗品是测试程序所必需的。此外，自动分析仪的巨大普及，减少了诊断时间，更好的患者之旅，并使医师之间的临床决策也有利于分部的未来前景。

This is evident with the launch of AQT90 FLEX analyzers, a PoC for D-dimer testing, introduced by Radiometer Limited, in February 2019. It is used for deep vein thrombosis cases in the lower limbs. With this PoC test, the results are provided within 21 minutes with a positive patient experience. Thus, the introduction of such novel products, expected to increase the market sale of reagents.

Insight by Testing Method

基于形式,全球肺动脉栓塞测试et is bifurcated as enzyme-linked immunosorbent assay (ELISA), latex-enhanced immuno-turbidimetric assays, fluorescence immunoassays, and others. In 2019, the ELISA market segment accounted for the largest market revenue share of over 35% in the global market because it is considered as the gold standard in the testing procedures, and the advent of automated ELISA systems also favoring the market growth. The fluorescence immunoassay segment is anticipated to register the highest market growth over the forecast period. Projected growth is due to the instrument’s high sensitivity, user-friendliness, and simpler assay procedures.

Geographic Overview

Geographically, the global D-dimer testing market is bifurcated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). North America market is the largest revenue contributor followed by Europe and the Asia Pacific region. In 2019, the North American market accounted for over 30% of the global market.

在市场上存在良好的临床基础设施，具有智力能力，适当的公司监管指南，以及该部门的创新是对该地区的D-Dimer测试行业增长的关键因素。据1920年1月发表的文章称，在患有神经障碍患者中鉴定了D-DIMER协议的必要提议。此外，有利的监管过程也有利于市场增长，例如，根据美国血液学学会2018年的指导方针，必然支持市场的专业人士。

亚太地区D-Dimer测试行业预计将在研究期间表现出最高的市场增长。提高医疗基础设施，私有病理实验室的出现等因素，以及具有提高医乐动娱乐官网疗意识和可支配收入的巨大患者基础是推动市场增长的重要因素。此外，政府在制定适当指导方针方面的作用也塑造了该地区未来的D-Dimer测试行业增长前景。

竞争洞察力

The prominent players operating in the D-dimer testing industry are Diazyme Laboratories, Inc., Siemen Healthineers, Thermo Fisher Scientific Inc., Roche Ltd., Abbott, Quidel Corporation, bioMerieux SA, WERFEN, HORIBA, Ltd., Biomedica Diagnostics, and Sekisui Diagnostics. The companies in the D-dimer testing industry are focusing on new D-dimer based assays. For instance, the U.S.-based Ortho Clinical Diagnostics in collaboration with Diazyme Laboratories introduced a new assay product “MicroTip Partnership Assay Program”.